SAE0064

Angiotensin Converting Enzyme-2, ACE2

Human recombinant, ≥1000000 U/mg, expressed in HEK 293 cells

• Synonim(y): ACE-related carboxypeptidase, ACE2, Angiotensin-converting enzyme homolog (ACEH), COVID-19 receptor, Coronavirus receptor, Metalloprotease MPROT15
• Numer WE: 3.4.17.23 (BRENDA, IUBMB)
• NACRES: NA.77
• UNSPSC Code: 12352200
• Specific activity: ≥1000000 U/mg
• Assay: ≥95% (SDS-PAGE)
• Biological source: human
• Recombinant: expressed in HEK 293 cells

Właściwości

• biological source: human
• Quality Segment: 100, 200
• recombinant: expressed in HEK 293 cells
• assay: ≥95% (SDS-PAGE)
• form: lyophilized powder
• specific activity: ≥1000000 U/mg
• mol wt: ~85.9 kDa by SDS-PAGE
• impurities: ≤1 EU/μg protein Endotoxin
• UniProt accession no.: Q9BYF1
• shipped in: ambient
• storage temp.: −20°C
• Gene Information: human ... ACE2(59272)

Opis

General description

The gene for angiotensin converting enzyme-2 (ACE-2) is mapped to human chromosome Xp22.2.[1] This protein is the first known human homologue of ACE. ACE2 has been identified from 5′ sequencing of a human heart failure ventricle cDNA library. It contains a signal peptide, one metalloprotease active site and a transmembrane domain. ACE-2 is a secreted and an integral membrane protein. It is expressed predominantly on the endothelium.

Application

Angiotensin Converting Enzyme-2 (ACE2) has been used in the ACE-2 inhibition assays for inhibitor selectivity studies.[2] It has also been used for identifying potent ACE2-blocking monoclonal antibodies in an on-chip assay and in human-ACE2-blocking assay using a biolayer interferometry biosensor. This approach serves for rational vaccine designing and for the selection of robust immunotherapeutic agents against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Biochem/physiol Actions

Recombinant human Angiotensin Converting Enzyme-2 (ACE-2) is expressed in human HEK 293 cells as a C-terminally flag and histidine-tagged glycoprotein with a calculated molecular mass of 85.9 kDa (amino acids Gln18-Ser740, with a C-terminal 10-His tag). The DTT-reduced protein migrates as a 90-120 kDa polypeptide on SDS-PAGE due to glycosylation. This protein is manufactured in human cells, with no serum. The human cells expression system allows human-like glycosylation and folding, and often supports higher specific activity of the protein.

The angiotensin converting enzyme-2 (ACE-2) functions as carboxydipeptidase.[1] The central role of ACE-2, is to counter ACE activity by reducing the bioavailability of angiotensin (Ang)-II and increasing the Ang(1-7) formation. ACE-2 is a part of the renin-angiotensin system (RAS). Many researches show that Ace-2 ensures the protection of peripheral tissues and might be efficient to treat RAS-related diseases. Also, an imbalance in Ace-2/Ang-(1-7) and ACE/Ang-II axes is important for the onset of cardiovascular diseases.[3] Severe acute respiratory syndrome (SARS) and human coronavirus (HCoV)-NL63 infection viruses has been shown to use its surface protein spike (glycoprotein) to bind to human ACE-2 receptor. The S protein is cleaved into subunits, S1 and S2 during the COVID-19 infection. S1 contains the receptor binding domain (RBD) which enables coronaviruses to bind to the peptidase domain (PD) of ACE2. Thus, ACE2 has become a high focus research target for COVID-19 infection.[4]

Physical form

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.

Other Notes

One unit is defined as the amount of enzyme required to cleave 1 picomole of the fluorogenic peptide substrate, Mca-YVADAPK(Dnp)-OH in one minute, in 37 °C, pH 7.5.

Ta strona może zawierać tekst przetłumaczony maszynowo.